Despite major advances in biologic and targeted synthetic therapies, the optimal timing for treatment initiation in psoriatic arthritis (PsA) remains uncertain—especially in the early, often undiagnosed, stages of...
Nancy Eisenberger,
DNP, FNP-BC
Family Nurse Practitioner, Arthritis, Rheumatic & Bone Disease Associates
Dual Biologic Therapy in Psoriatic Arthritis: A Promising Approach
Biologic therapies have significantly improved outcomes in immune-mediated diseases like rheumatoid arthritis (RA) and psoriatic arthritis (PsA), yet some patients...
Psoriatic arthritis (PsA) is often linked to metabolic syndrome, which involves inflammation and cytokines like interleukin (IL)-17 and IL-23. Studies...
Bimekizumab: BE OPTIMAL Trial of Psoriatic Arthritis
The BE OPTIMAL trial, a phase 3 randomized, double-blind, placebo-controlled study, evaluated the efficacy and safety of bimekizumab in biologic-naive...
More biologic disease-modifying antirheumatic drugs (bDMARDs) are available now, with distinct mechanisms of action that have broadened treatment options for...
GRAPPA Consensus on Comprehensive Treatment Recommendations for Psoriatic Arthritis
The objective of this study was to develop comprehensive treatment recommendations for the various clinical manifestations of psoriatic arthritis (PsA),...
